At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SKYE Skye Bioscience Inc.
Pre-Market Trading 05-17 04:33:32 EDT
12.25
-0.43
-3.39%
High13.44
Low12.15
Vol46.18K
Open13.44
D1 Closing12.68
Amplitude10.17%
Mkt Cap343.77M
Tradable Cap142.93M
Total Shares28.06M
T/O575.60K
T/O Rate0.40%
Tradable Shares11.67M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Skye Bioscience Files For Mixed Shelf Of Up To $300 Mln
Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.